On the 23rd, the news that "the price of Lianhua Qingwen's 'out of stock' has increased, and the price of some pharmacies has increased by more than 50%" was on the hot search.

　　According to media reports, some pharmacies have raised the price of Lianhua Qingwen Capsules to varying degrees.

Among them, the price of Lianhua Qingwen Capsules with a specification of 0.35g*48 capsules/box has increased significantly.

There is a pharmacy located in Heyuan City, Guangdong Province. The current price of Lianhua Qingwen Capsules in the size of 0.35g*48 capsules/box is 46 yuan/box.

If calculated based on the usual price of about 30 yuan/box in the past, the price has increased by more than 50%.

　　Regarding the reason for the price increase, the report stated that a staff member of the pharmacy said, "Lianhua Qingwen has recently increased its price, and there have been a lot of people buying it recently. The manufacturer's price has increased, and the goods cannot be ordered. The price has been adjusted." Some pharmacy employees also said, "The purchase price is expensive."

　　So, has Yiling Pharmaceutical, the manufacturer of Lianhua Qingwen, raised the price of related drugs?

Is it common for pharmacies to increase prices and sell Lianhua Qingwen?

　　In this regard, the relevant person in charge of Yiling Pharmaceutical Co., Ltd. responded to a reporter from Securities Times·e Company on the 23rd, saying, "The company has not raised the price of Lianhua Qingwen-related drugs."

　　The reporter of e company also contacted a leading listed company of instant digital pharmacy, which has established a network of 351 smart pharmacies in 17 cities across the country.

The relevant person in charge of the company told reporters that the prices of anti-epidemic drugs such as Lianhua Qingwen on the platform have not changed, and there is no news of manufacturers raising prices. The fluctuations in drug prices in various pharmacies may be due to different promotions at different times.

"In terms of supply, on the whole, the supply of Lianhua Qingwen and other medicines on our platform can be guaranteed, and no out-of-stock phenomenon has been found. Sometimes orders cannot be placed at night because of backstage replenishment, and we will also increase procurement and supply. .”

　　Yiling Pharmaceutical released a statement

　　According to recent market rumors, Lianhua Qingwen Capsules and Lianhua Qingwen Granules have been sold out in some areas. This is also a major background for the fact that "the price of some pharmacies has increased by more than 50%" this time.

　　In response to the rumor of selling out of stock, the relevant person in charge of Yiling Pharmaceutical previously responded to the reporter of e Company, saying that Yiling Pharmaceutical has been doing a series of work to increase production capacity in the past two years, and the current production capacity has been greatly increased. There are factories in Shijiazhuang, Beijing, Hengshui and other places for the production of plague products, and the current production is basically not affected.

It also stated that the production plan of Yiling Pharmaceutical is to "determine production based on sales", and can adjust the production plan in time according to market demand to ensure market supply, and the current sales are also normal.

　　It is worth mentioning that under the background that Lianhua Qingwen and other products are "out of stock" in some areas, a number of counterfeit "Lianhua" series products have recently appeared on the market.

In this regard, on November 22, Yiling Pharmaceutical issued a statement stating that there have been many names on the market recently, such as "Lianhua Qingwen Tea", "Lianhua Qingwen Tea", "Lianhua Qingwen Cream", "Lianhua Qingwen Oral Liquid" and "Lianhua Qingwen Oral Liquid". These products are not produced, sold or authorized to be produced and sold by Yiling Pharmaceutical.

Yiling Pharmaceutical stated that the above-mentioned products are similar or similar to the brand name and outer packaging of the company's "Yiling Lianhua Qingwen" (drug) and the Lianhua brand "Lianhua Qingfei Tea" (drink) produced by its subsidiaries. , It is very easy to confuse, and consumers have had major misunderstandings about this.

Yiling Pharmaceutical also mentioned that "Lianhua Qingwen", "Lianhua", "Lianhuaqing" and "Lianhuaqingfei" are legally registered trademarks of the company and have obtained the exclusive right to use trademarks, while the "Lianhuaqing" produced by it The appearance design patent of "Wen Capsule" is not authorized to be used by others.

The company reserves the right to pursue the relevant legal responsibilities of the person responsible for the production and sale of counterfeit and confusing company products and other violations of the company's trademark exclusive rights and other legal rights and interests.

recent stock price rise

　　The main business of Yiling Pharmaceutical is the research and development, production and sales of patented innovative traditional Chinese medicines. The Lianhua Qingwen series of products produced and sold by it have attracted attention because they have been included in the diagnosis and treatment of new coronary pneumonia many times.

　　It is worth mentioning that, as the manufacturer of Lianhua Qingwen, Yiling Pharmaceutical has recently been sought after by funds in the secondary market.

　　According to market data, in less than two months since the end of September, the stock price of Yiling Pharmaceutical has risen all the way from around 18.8 yuan.

Especially since entering November, with the increase in trading volume, Yiling Pharmaceutical has issued two notices of change due to the continuous surge in stock price, and hit a record high of 48.66 yuan per share on November 21.

However, the stock price has been pulled back in the past two trading days, and the latest closed at 39.99 yuan.

　　From the perspective of operating performance, in the first three quarters of this year, Yiling Pharmaceutical achieved a total operating income of 7.946 billion yuan, a year-on-year decrease of 2.04%; net profit attributable to the parent company was 1.414 billion yuan, a year-on-year increase of 15.58%, and non-net profit was 1.416 billion yuan, a year-on-year increase 20.60%; of which, in the single quarter of Q3, the total operating income was 2.38 billion yuan, a year-on-year increase of 7.41%; the net profit attributable to the parent company was 366 million yuan, a year-on-year increase of 40.92%, and the non-net profit was 365 million yuan, a year-on-year increase of 49.32%.

　　In terms of products, since the beginning of this year, the sales of Lianhua Qingwen and other drugs produced by Yiling Pharmaceutical have increased significantly.

According to the announcement, in the first three quarters, Yiling Pharmaceutical’s main product, Tongshenqi, was affected by various factors such as the epidemic, and its revenue declined slightly compared with the same period in 2021. However, since Q3, cardiovascular and cerebrovascular products have shown a gradual recovery trend. Vascular products achieved a slight year-on-year growth; Lianhua Qingwen’s revenue still achieved year-on-year growth under a relatively high base in 2021 due to its special product attributes for the treatment of new crowns, flu and colds.

　　After the release of the third quarterly report, Yiling Pharmaceutical also attracted research from many institutional investors.

Talking about the overseas export of Lianhua Qingwen, the company said that at present, Lianhua Qingwen has been registered and approved for listing in more than 20 countries and regions. This year, Lianhua Qingwen still continued the good sales trend last year. In the future, the company will continue to promote the overseas registration and sales of Lianhua Qingwen.